Developability refers to the likelihood that an antibody candidate will become a
manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug …

The search for innovative anti-cancer drugs remains a challenge. Over the past three
decades, antibodies have emerged as an essential asset in successful cancer therapy. The …

Bispecific antibodies (bsAbs) were first described by Nisonoff and coworkers over 50 years
ago wherein a mild redox reaction was used to link two rabbit binding F (ab') 2 fragments [1 …

Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding
activity, which permits simultaneous targeting of antigens and synergistic binding effects …

Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the
biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago …

Despite the large number of existing bispecific antibody (bsAb) formats, the generation of
novel bsAbs is still associated with development and bioprocessing challenges. Here, we …

Colorectal cancer remains a major cause of mortality in the USA, despite advances in
prevention and screening. Existing therapies focus primarily on generic treatment such as …

In this dispensation of the fourth industrial revolution, protein engineering has become a
popular approach for increasing enzymatic activity, stability, and titer in the biosynthesis of …

The intestinal epithelial receptor Guanylyl Cyclase C (GUCY2C) is a tumor-associated cell
surface antigen expressed across gastrointestinal malignancies that can serve as an …

Antibodies that recognize specific protein conformational states are broadly important for
research, diagnostic and therapeutic applications, yet they are difficult to generate in a …